Market Indices
Latest News
 |
from Barclays issued a price target of $16.50 for April 17, 2026 VIV -1.14% |
| ||
| ||
|
Price Targets
from Barclays issued a price target of $16.50 for VIV on 2026-04-17 09:29:18.The adjusted price target was set to $16.50.At the time of the announcement, VIV was...
April 17, 2026 VIV -1.14%
from BNP Paribas issued a price target of $101.00 for SHEL on 2026-04-17 09:08:32.The adjusted price target was set to $101.00.At the time of the announcement, SHEL...
April 17, 2026 SHEL 1.85%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| CNF CNFinance Holdings Limite | 3.46
16.72% | ||||||||||||||||||
| SMMT Summit Therapeutics Inc. | 24.42
15.63% | ||||||||||||||||||
| IMOS ChipMOS TECHNOLOGIES Inc. | 49.17
14.14% | ||||||||||||||||||
| CMPS COMPASS Pathways plc | 6.66
11.75% | ||||||||||||||||||
| BZUN Baozun Inc. | 2.99
11.57% | ||||||||||||||||||
| HIMX Himax Technologies, Inc. | 11.27
10.71% | ||||||||||||||||||
| CLGN CollPlant Biotechnologies | 0.35
10.35% | ||||||||||||||||||
| DAO Youdao, Inc. | 10.66
9.90% | ||||||||||||||||||
Annual/Quarterly Reports Summary
Summit Therapeutics Inc. (SMMT) Quarterly Report: What Does It Reveal About Their Sector Performance
May 1, 2025 SMMT 15.63%
In a landscape of rising revenues and increasing operational costs, the company navigates challenges with a focus on innovation and sustainability. Despite a dip in net income and profit declines...
February 5, 2025 TEVA -1.11%
In a year marked by resilience, the company celebrated record revenues of $25 billion, driven by strong ticket sales and operational efficiency. With a focus on North America, it reduced...
January 27, 2025 CUK -5.31%